On May 2, 2023 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, reported the presentation of five abstracts, including one late-breaking oral presentation, at this year’s American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, taking place in Los Angeles, California from May 16-20, 2023 (Press release, 2seventy bio, MAY 2, 2023, View Source [SID1234630820]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The late-breaking abstract featuring early findings from the ongoing Phase 1 PLAT-08 trial in collaboration with Seattle Children’s Therapeutics, evaluating SC-DARIC33 in pediatric and young patients with relapsed/refractory AML, will be presented on Friday, May 19. SC-DARIC33 is an investigational CD33-targeted chimeric antigen receptor (CAR) T cell therapy that utilizes 2seventy bio’s proprietary Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) T cell platform, a regulatable CAR T cell technology. A second oral presentation will feature preclinical data on enhanced anti-AML potency of DARIC33 by coupling it with iSynPro-IL-15, an encoded IL-15 expression module driven by an antigen-regulated synthetic promoter that will be presented on Thursday, May 18.

"At 2seventy bio, we are focused on utilizing our advanced scientific toolkit to develop innovative cell therapies with the goal of achieving tumor control and elimination across hematologic cancers and solid tumors," said Philip Gregory, D.Phil., chief scientific officer, 2seventy bio. "Our data at ASGCT (Free ASGCT Whitepaper) demonstrate continued progress in deepening our next-generation cell therapy product engine and pipeline, particularly early findings for DARIC33 that continue to reinforce its potential as a new T cell therapy approach in AML, CBLB gene edited CAR T cell therapy advancements with bbT369, and our potency enhanced MAGE-A4 TCR program in solid tumors. We are also revealing, for the first time, our novel receptor architecture called RESET, which is designed to blend both the sensitivity of TCRs with the ease of tumor antigen targeting through CARs, all within a drug-regulated CAR T platform."

Key data presentations include:

Details of 2seventy bio Presentations at ASGCT (Free ASGCT Whitepaper) Annual Meeting
Late-breaking Oral Presentation [#3092]: First in human studies show activation of SC-DARIC33, a rapamycin-regulated anti-CD33 CAR T cell therapy, in patients with AML
Presenting Author: Jacob Appelbaum, M.D., Ph.D., Hematologist, Fred Hutch Cancer Center & Acting Instructor, Hematology, Univ. of Washington
Date/Time: Friday, May 19, 2023, 11:30 – 11:45am PT

Oral Presentation [#148]: Enhanced anti-AML potency of DARIC33 by iSynPro-IL-15*: an IL-15 expression module driven by a tightly regulated synthetic promoter activated by antigen receptor signaling
Presenting Author: Jacob Appelbaum, M.D., Ph.D., Hematologist, Fred Hutch Cancer Center & Acting Instructor, Hematology, Univ. of Washington
Date/Time: Thursday, May 18, 2023, 2:30 – 2:45pm PT

Poster Presentation [#585]: bbT369, a clinical-stage dual-targeted and CBLB gene edited autologous CAR T product for non-Hodgkin Lymphoma, shows edit driven enhanced activity in preclinical in vitro and in vivo models
Presenting Author: Michael Certo, 2seventy bio
Date/Time: Wednesday, May 17, 2023, 12:00 – 2:00pm PT

Poster Presentation [#612]: Novel TGFb switch receptor drives robust MAGE-A4 TCR anti-tumor activity with a favorable safety profile
Presenting Author: Esteban Carrizosa, 2seventy bio
Date/Time: Wednesday, May 17, 2023, 12:00 – 2:00pm PT

Poster Presentation [#608]: RESET: a novel TCR coupled antigen receptor displaying superior targeting sensitivity and pharmacologically controlled anti-tumor activity
Presenting Author: Jardin Leleux, 2seventy bio
Date/Time: Wednesday, May 17, 2023, 12:00 – 2:00pm PT

About SC-DARIC33

2seventy bio is collaborating with Seattle Children’s Therapeutics to rapidly accelerate development of potential new therapies for patients with acute myeloid leukemia (AML). This research collaboration is investigating potential solutions to two challenges in treating AML: disease heterogeneity and toxicity due to shared expression of targets between tumor and normal tissue.

SC-DARIC33 is an investigational, pharmacologically controlled CD33-targeted autologous T cell product that utilizes 2seventy bio’s proprietary Dimerizing Agent Regulated Immunoreceptor Complex (DARIC) T cell platform, a regulatable CAR T cell technology. DARIC T cells are intended to be switched from "OFF" to "ON" in the presence of rapamycin, such that while in the "ON" state the T cell is poised to be activated upon encounter with its target antigen.

PLAT-08, the Phase 1 study of SC-DARIC33 in relapsed/refractory pediatric AML, led by Seattle Children’s Therapeutics, couples 2seventy bio’s DARIC T cell platform with Seattle Children’s world-class bench-to-bedside expertise in oncology cell therapies. This study is a first-in-human investigation of the DARIC T cell platform and is open for enrollment at Seattle Children’s. For more information visit: clinicaltrials.gov using identifier NCT05105152.

SC-DARIC33 is not approved for any indication in any geography.

About bbT369

bbT369 is an investigational dual-targeting CAR T cell therapy with a gene edit for patients with relapsed and/or refractory B-NHL.

bbT369 has three layers of innovation, purposely designed to address the potential mechanisms of anti-CD19 CAR T cell therapy failure: dual targeting (CD79a/CD20), split co-stimulation signaling technology, and a gene edit to remove the function of CBLB.

In December 2021, the FDA cleared the Investigational New Drug (IND) application for bbT369. The clinical development program for bbT369 includes the Phase 1/2 CRC-403 study (NCT05169489). Safety and potential efficacy of bbT369 in patients with specific subtypes of relapsed and/or refractory B-NHL will be assessed, including patients who relapsed after CD19 CAR T cell therapy as well as patients who are CAR-naïve.

bbT369 is not approved for any indication in any geography.

About the MAGE-A4 Program

MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. Our program employs a highly potent TCR discovered in our MediGene collaboration that recognizes HLA-presented MAGE-A4 peptides and further enhances the potency of these re-directed T cells using our CTBR12 TGF-beta "flip" receptor technology — which converts the immunosuppressive effects of TGF-beta into an activation signal for the T cells. Regeneron and 2seventy bio are co-developing the program under their collaboration entered into in 2018.